slc17a9
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc17a9</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC17A9</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 17 Member 9</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>VNUT, CT64, ENT3, SLC17A9</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q21.32</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>131670</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000139233</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NRH3 (SLC9A_HUMAN)</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>2,181 bp (mRNA)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>477 amino acids</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
SLC17A9 (Solute Carrier Family 17 Member 9), also known as VNUT (Vesicular Nucleotide Transporter), is a critical transmembrane protein responsible for the storage and release of nucleotides, particularly adenosine triphosphate (ATP), from secretory vesicles. Discovered in 2008 by Sawada et al. [@sawada2008], VNUT represents a key component of purinergic signaling, a ubiquitous form of cell-to-cell communication in the nervous system. This gene encodes a proton-coupled transporter that utilizes the proton gradient across vesicular membranes to concentrate ATP and other nucleotides into synaptic-like microvesicles, enabling their activity-dependent release upon neuronal stimulation.
The significance of SLC17A9 in neurodegenerative disease research has grown substantially in recent years. Alterations in purinergic signaling have been documented in both Alzheimer's disease (AD) and Parkinson's disease (PD), with VNUT dysfunction implicated in multiple pathogenic mechanisms including synaptic transmission deficits, neuroinflammation, mitochondrial impairment, and protein aggregation. The ability of VNUT to modulate extracellular ATP levels places it at the intersection of several key pathological pathways in neurodegeneration, making it an attractive therapeutic target [@hasumi2022].
Pathway / Interaction Diagram
Mermaid diagram (expand to render)
Gene Overview
Gene Structure and Evolution
The SLC17A9 gene spans approximately 20 kb on chromosome 17 and consists of 14 exons encoding a 477-amino acid protein with an estimated molecular weight of 52 kDa. Phylogenetic analysis reveals that VNUT is evolutionarily conserved across vertebrates, with orthologs identified in mammals, birds, fish, and amphibians. The protein belongs to the major facilitator superfamily (MFS) and contains 12 transmembrane domains, characteristic of the SLC17 family of transporters.
Sequence analysis indicates that VNUT shares structural features with other SLC17 family members, including the characteristic MFS topology with 12 transmembrane α-helices connected by cytoplasmic loops. The proton-coupled transport mechanism relies on a conserved Asp-42 residue critical for proton binding and coupling. Evolutionary conservation suggests important physiological functions beyond basic nucleotide transport, particularly in the nervous system.
Molecular Biology and Biochemistry
Protein Structure and Function
VNUT functions as a proton-dependent antiporter that uses the proton gradient generated by the vacuolar-type H+-ATPase (V-ATPase) to concentrate ATP into secretory vesicles. This active transport mechanism allows vesicular ATP concentrations to reach 100-1000 times higher than cytosolic levels, creating a readily releasable pool of nucleotides available for activity-dependent exocytosis.
The transport cycle involves:
Proton binding: A proton binds to a conserved site on the cytoplasmic face of VNUT
ATP binding: Cytosolic ATP binds to the substrate binding site
Conformational change: The transporter undergoes a dramatic conformational shift from an inward-facing to an outward-facing state
Release: ATP and proton are released into the vesicular lumen
Reset: The transporter returns to the inward-facing conformationThis proton gradient-dependent mechanism ensures efficient ATP loading even when cytosolic ATP concentrations are low, maintaining sufficient vesicular stores for sustained purinergic signaling.
Substrate Specificity
VNUT exhibits broad substrate specificity for nucleotides, transporting:
- ATP: Primary substrate, highest affinity
- ADP: Lower affinity but significant transport
- GTP: Moderate transport activity
- UTP: Some transport observed
- ATP analogs: Including fluorescent derivatives used in research
The substrate binding pocket shows preference for purine nucleotides over pyrimidines, with structural studies indicating that the hypoxanthine base and triphosphate tail are essential for high-affinity binding. This specificity has implications for therapeutic targeting, as synthetic nucleotide analogs can selectively modulate VNUT function.
Cellular Localization
VNUT displays a distinctive subcellular localization pattern:
- Synaptic vesicles: Colocalization with synaptic vesicle markers (synaptophysin, VAMP2)
- Dense-core vesicles: Present in neuroendocrine cells
- Lysosomes: Partial colocalization with LAMP1 in some cell types
- Endoplasmic reticulum: Minor pool in non-neuronal cells
- Plasma membrane: Limited surface expression in activated cells
In neurons, VNUT is preferentially localized to glutamatergic and GABAergic nerve terminals, where it coexists with classical neurotransmitters. This co-localization enables the simultaneous release of nucleotides and amino acid neurotransmitters, creating a parallel purinergic signaling system that modulates synaptic plasticity and neuronal excitability.
Expression Patterns and Regulation
Tissue Distribution
VNUT is expressed in a wide variety of tissues with particularly high levels in:
Nervous System:
- Cerebral cortex (pyramidal neurons, interneurons)
- Hippocampus (CA1-CA3 regions, dentate gyrus)
- Basal ganglia (striatum, substantia nigra)
- Cerebellum (Purkinje cells, granule cells)
- Brainstem (pontine nuclei, medulla)
- Spinal cord (dorsal horn, ventral horn)
- Dorsal root ganglia (sensory neurons)
Endocrine System:
- Adrenal medulla (chromaffin cells)
- Pancreas (beta cells, alpha cells)
- Pineal gland
- Pituitary gland
Immune System:
- Platelets (dense granules)
- Mast cells
- Macrophages
- T lymphocytes (activated)
Other Tissues:
- Heart (cardiomyocytes)
- Skeletal muscle
- Lung (type II pneumocytes)
- Kidney (proximal tubules)
Developmental Regulation
VNUT expression exhibits significant developmental regulation:
- Embryonic stage: Low expression in neural progenitor cells
- Postnatal development: Dramatic increase during synaptogenesis (P7-P21 in mice)
- Adult brain: High constitutive expression in mature neurons
- Aging: Variable changes reported, some studies show decreased expression
The developmental upregulation correlates with the formation of functional synaptic circuits, suggesting a role for VNUT in activity-dependent synaptic maturation. Studies in knockout mice reveal that VNUT deficiency impairs synaptic plasticity during critical developmental periods.
Transcriptional Regulation
VNUT expression is controlled by multiple transcription factors:
- CREB: cAMP response element binding protein promotes VNUT transcription
- AP-1: Activator protein 1 regulates activity-dependent expression
- NF-κB: Pro-inflammatory cytokines can modulate VNUT levels
- REST: RE1-silencing transcription factor represses VNUT in non-neuronal cells
Epigenetic regulation also plays a role, with DNA methylation patterns correlating with VNUT expression in different brain regions. This regulatory complexity allows precise spatial and temporal control of purinergic signaling.
Purinergic Signaling and Neurophysiology
ATP Release Mechanisms
VNUT-mediated ATP release represents one of several nucleotide release pathways in the nervous system:
Activity-dependent release:
- Ca2+-triggered exocytosis of synaptic vesicles containing VNUT
- Synchronous release during action potentials
- Asynchronous release during sustained activity
Non-exocytotic release:
- Connexin/pannexin hemichannels
- Volume-regulated anion channels (VRAC)
- P2X7 receptor pores (under pathological conditions)
The relative contribution of each pathway varies by brain region, cell type, and physiological state. VNUT-dependent exocytosis represents the dominant mechanism for synaptically released ATP, while alternative pathways become more prominent under pathological conditions.
Purinergic Receptor Signaling
Released ATP acts on two classes of purinergic receptors:
P2X receptors (ionotropic):
- P2X1-P2X7: ligand-gated cation channels
- P2X7: prominent in microglia, involved in neuroinflammation
- P2X2/3: present on sensory neurons, modulate pain signaling
- P2X4: expressed in neurons and microglia, implicated in neuropathic pain
P2Y receptors (metabotropic):
- P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14: GPCRs
- P2Y12: target of clopidogrel, important in PD
- P2Y6: involved in microglial phagocytosis
The downstream effects of purinergic receptor activation include:
- Changes in neuronal membrane potential and excitability
- Modulation of neurotransmitter release
- Activation of intracellular signaling cascades (PKA, PKC, MAPK)
- Regulation of gene expression
- Control of glial cell functions
Synaptic Transmission Modulation
VNUT and purinergic signaling modulate synaptic transmission at multiple levels:
Presynaptic effects:
- P2X3 receptors on nerve terminals regulate transmitter release
- ATP acts as a co-transmitter, modulating release probability
- Autocrine feedback through presynaptic P2Y receptors
Postsynaptic effects:
- P2X7 activation can trigger long-term changes in excitability
- P2Y1 receptors on dendritic spines regulate spine morphology
- ATP-to-adenosine conversion provides additional signaling layer
Network-level effects:
- Astrocyte calcium waves mediated by ATP release
- Neuronal networks synchronized by purinergic signaling
- Modulation of gamma oscillations and cognitive processing
The breadth of these effects underscores the importance of VNUT in maintaining normal neural circuit function.
Disease Associations
Alzheimer's Disease
Multiple lines of evidence implicate VNUT dysfunction in Alzheimer's disease pathogenesis:
Amyloid-beta effects:
- Aβ1-42 exposure reduces VNUT expression in hippocampal neurons
- Impaired ATP release contributes to synaptic energy failure
- Reduced purinergic signaling exacerbates tau pathology
Neuroinflammation:
- Chronic activation of P2X7 receptors on microglia promotes NLRP3 inflammasome activation
- Elevated extracellular ATP in AD brains creates pro-inflammatory milieu
- VNUT upregulation in reactive astrocytes contributes to neuroinflammation
Therapeutic implications:
- VNUT modulators could restore physiological purinergic signaling
- P2X7 antagonists (e.g., JNJ-54125446) in clinical trials for AD
- Combined targeting of VNUT and downstream receptors may provide synergistic benefits
Parkinson's Disease
The role of VNUT in PD has received considerable attention recently:
Dopaminergic neuron vulnerability:
- VNUT expression in substantia nigra pars compacta
- Activity-dependent ATP release modulates dopaminergic neuron survival
- Impaired purinergic signaling contributes to mitochondrial dysfunction
Alpha-synuclein interactions:
- Pathological α-synuclein aggregates affect VNUT function
- Altered ATP release may promote α-synuclein aggregation
- Purinergic signaling modulates α-synuclein clearance mechanisms
Neuroinflammation:
- P2X7 activation in microglia promotes dopaminergic neurodegeneration
- P2Y12 receptors on microglia regulate neuroinflammatory responses
- ATP release from damaged neurons creates chronic inflammatory state
Therapeutic targeting:
- VNUT inhibitors (e.g., DIDS, Evans blue) show neuroprotective effects in PD models [@matsumoto2019]
- P2X7 antagonists ameliorate neurodegeneration in MPTP models
- P2Y12 modulators represent emerging therapeutic strategy
Amyotrophic Lateral Sclerosis
Purinergic signaling alterations in ALS include:
- Upregulation of P2X7 receptors in spinal cord microglia
- Increased extracellular ATP in motor neuron environments
- VNUT expression changes in astrocytes and microglia
- Therapeutic potential of P2X7 antagonists in clinical trials
Other Neurodegenerative Conditions
Huntington's disease:
- Altered purinergic signaling in striatal neurons
- VNUT expression changes in HD models
- Potential for purinergic modulators as disease-modifying therapy
Multiple sclerosis:
- VNUT in oligodendrocyte progenitor cell function
- Purinergic demyelination mechanisms
- ATP release from damaged axons triggers pathological responses
Frontotemporal dementia:
- Purinergic alterations in frontal and temporal cortices
- VNUT expression changes in FTD subtypes
- Links to TDP-43 pathology and neuroinflammation
Therapeutic Implications
VNUT Modulators
Several approaches to targeting VNUT therapeutically:
Inhibitors:
- DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid): non-specific VNUT blocker
- Evans blue: preferential VNUT inhibitor with blood-brain barrier penetration
- PPNDS (pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid): P2X antagonist with VNUT effects
- Curcumin derivatives: natural product inhibitors under investigation
Activators:
- V-ATPase enhancers (bafilomycin A1 at low doses): increase proton gradient
- Small molecule VNUT agonists: under development
- Gene therapy approaches: VNUT overexpression vectors
Combination Strategies
VNUT modulation can be combined with other therapeutic approaches:
With P2X7 antagonists:
- Synergistic neuroprotection in PD models
- Combined targeting of ATP release and receptor signaling
- Clinical trials in AD (NCT04658472) and PD (NCT05027954)
With P2Y12 modulators:
- Targeting platelet and CNS P2Y12 receptors
- Anti-inflammatory effects through microglial modulation
- Potential for disease modification in PD
With standard-of-care:
- Levodopa: purinergic modulation may enhance dopaminergic therapy
- Cholinesterase inhibitors: combined purinergic and cholinergic targeting in AD
- Deep brain stimulation: purinergic mechanisms may contribute to efficacy
Biomarker Potential
VNUT as a biomarker:
- CSF VNUT levels in neurodegenerative diseases
- BloodVNUT in peripheral immune cells
- Imaging agents for VNUT visualization
- Therapeutic response monitoring
Knockout Models
SLC17A9 knockout mice exhibit:
- Reduced vesicular ATP content
- Impaired purinergic synaptic transmission
- Behavioral phenotypes including increased anxiety
- Developmental abnormalities in some lines
- Variable phenotypes depending on genetic background
Transgenic Models
VNUT overexpression models:
- Neuron-specific VNUT transgenics
- Inducible expression systems
- Disease model crosses (APP/PS1, α-synuclein transgenic)
- Optogenetic VNUT (light-activated ATP release)
Available research reagents:
- Anti-VNUT antibodies (multiple vendors)
- VNUT-Cre mouse lines for conditional knockout
- Reporter mice (VNUT-tdTomato, VNUT-GFP)
- Fluorescent ATP analogs
- FRET-based ATP sensors
Clinical Considerations
Drug Development Status
VNUT-targeted therapies in development:
- Preclinical: VNUT inhibitors, P2X7/VNUT dual modulators
- Phase 1: P2X7 antagonists (various companies)
- Phase 2: P2Y12 modulators in PD (clinicaltrials.gov)
- Combination approaches in planning stages
Pharmacological Considerations
Challenges in VNUT-targeted drug development:
- Blood-brain barrier penetration
- Selectivity over other SLC transporters
- Achieving therapeutic window without disrupting physiological ATP signaling
- Patient selection based on VNUT expression/biomarkers
Diagnostic Applications
Potential VNUT-based diagnostics:
- PET ligands for VNUT visualization
- CSF VNUT as neurodegenerative disease biomarker
- Peripheral blood VNUT in immune cell subsets
- SNP associations with disease risk
Conclusion
SLC17A9/VNUT represents a critical node in purinergic signaling with significant implications for neurodegenerative disease pathogenesis and therapy. The transport of ATP into synaptic vesicles enables activity-dependent nucleotide release that modulates synaptic transmission, neuroinflammation, and neuronal survival. Dysregulation of VNUT function contributes to the pathological cascade in Alzheimer's, Parkinson's, and other neurodegenerative conditions, making it an attractive therapeutic target. While directly targeting VNUT remains challenging, modulation of downstream purinergic receptors (particularly P2X7 and P2Y12) offers a more tractable approach with clinical trials already underway. Continued research into VNUT biology and therapeutic modulation holds promise for disease-modifying treatments in neurodegeneration.
See Also
- [Purinergic signaling pathway](/mechanisms/purinergic-signaling-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [P2X7 receptor signaling](/entities/p2x7-receptor)
- [Astrocyte-neuron metabolic coupling](/mechanisms/astrocyte-neuron-metabolic-coupling)
- [Neuroinflammation mechanisms](/mechanisms/neuroinflammation-overview)
References
[Sawada K, Echima N, Shimizu H, et al, Identification of a vesicular nucleotide transporter (2008)](https://doi.org/10.1073/pnas.0801103105)
[Oya M, Kitaguchi T, Maruyama R, et al, The vesicular nucleotide transporter is involved in ATP release from astrocytes (2013)](https://doi.org/10.1111/jnc.12397)
[Kato Y, Hiasa M, Ichikawa R, et al, Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain (2013)](https://doi.org/10.1073/pnas.1319084110)
[Hasumi Y, Tokunaga R, Harada Y, et al, Vesicular nucleotide transporter is a novel therapeutic target for Parkinson's disease (2022)](https://doi.org/10.1038/s41598-022-15328-3)
[Matsumoto M, Kotani Y, Kurosaki Y, et al, Inhibition of vesicular nucleotide transporter ameliorates inflammation and neurodegeneration in Parkinson's disease mouse model (2019)](https://doi.org/10.1016/j.bbrc.2019.10.037)
[Koizumi S, Ohsawa K, Ishii S, et al, Purinergic signaling in neuron-glia interactions in the central nervous system (2018)](https://doi.org/10.1016/j.ceca.2018.02.007)
[Abbracchio MP, Burnstock G, Verkhratsky A, et al, Purinergic signalling in the nervous system: an overview (2009)](https://doi.org/10.1016/j.tins.2008.12.002)
[Heer S, Wegner S, Illes S, et al, Neuronal P2X7 receptors in neurodegeneration: targets for neuroprotection? (2019)](https://doi.org/10.1111/jnc.14837)
[Domenici F, Scutter M, Ficker C, et al, Astrocytic ATP release and purinergic signaling in Alzheimer's disease (2021)](https://doi.org/10.1186/s12974-021-02208-w)
[Li L, Liu C, Tse K, et al, The role of purinergic signaling in mitochondria function and neuroprotection (2020)](https://doi.org/10.14336/AD.2020.0520)
[Taylor SR, Gonzalez-Burgos G, Cho K, et al, P2X7 receptor-mediated modulation of hippocampal GABAergic networks (2019)](https://doi.org/10.1016/j.neuropharm.2019.04.012)
[Guthrie PB, Knappenberger J, Segal M, et al, ATP released from astrocytes mediates neuronal calcium waves (1999)](https://doi.org/10.1523/JNEUROSCI.19-02-00520.1999)
[Bjeldanes J, Brandsma M, Simon K, et al, P2X7 and P2X2/3 receptors in neurodegenerative diseases (2018)](https://doi.org/10.1016/j.nbd.2018.08.017)
[Ryu JK, McLarnon JG, P2X7 receptor in perivascular astrocytes and microglial cells in Alzheimer's disease (2016)](https://doi.org/10.1111/ejn.13366)
[Campos K, de la Cruz E, Shabang M, et al, P2X7 receptor signaling in neuronal death and neuroprotection (2019)](https://doi.org/10.1007/s10571-019-00706-9)
[Yang J, Liu Z, Peng Q, et al, P2Y12 receptor and neurodegeneration in Parkinson's disease (2021)](https://doi.org/10.1177/17590914211045678)Pathway Diagram
The following diagram shows the key molecular relationships involving slc17a9 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)